FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: A randomized phase III study (EAGLE study)

Japanese Journal of Clinical Oncology

Volumn 42, Issue 2, 2012, Pages 134-138

  Mishima, Hideyuki ^a   Oba, Koji ^b   Sakamoto, Junichi ^c   Muro, Kei ^d   Yoshino, Takayuki ^e   Hyodo, Ichinosuke ^f   Maehara, Yoshihiko ^g  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

Author keywords

Advanced metastatic colorectal cancer; Bevacizumab; Beyond progression; FOLIRI; Irinotecan

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DOSE COMPARISON; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84856625485     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr180     Document Type: Article

References (21)

1. Center for Cancer Control and Information Services, National Cancer Center, Japan. Statistics. http://ganjoho.jp/public/statistics/index.html (in Japanese).
2. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008;9:730-56.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
4. Colorectal cancer treatment guideline for doctor ver, 2009. http://www.jsccr.jp/guideline.html.
5. Tournigand C, Andre T, Achille E, Flesh M, Mery-Migmard D, Quinaux E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
6. Senellart H, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, et al. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer (mCRC): 12-month results of a phase II study (bevacolor). In: 2008 Gastrointestinal Cancers Symposium (abstract 493).
7. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
8. Vosseler S, Mirancea N, Bohlen P, Mueller MM, Fusenig NE. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005;65:1294-305.
9. Kamba T, Tam B, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-76.
10. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004;165:35-52.
11. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
12. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumor genesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-97.
13. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-34.
14. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
15. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
16. Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. BO17704 (AVAiL): a phase III randomized study of first line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Ann Oncol 2008;19 (late-breaking abstract 1).
17. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
18. Miles D, Chan A, Romieu G, Dirix LY, Cortes J, Pivot X, et al. A randomized, double-blind study of bevacizumab in combination with docetaxel as first-line treatment of patients with HER2-negative locally recurrent or metastatic breast cancer: efficacy and safety: AVADO. J Clin Oncol 2008;26 (meeting abstracts): LBA1011.
19. Horita Y, Hirashima Y, Yamada Y, Kato K, Nakamoto A, Nishitani H, et al. Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy. 2009 Gastrointestinal Cancers Symposium (abstract 380).
20. Greenwood M. The Natural Duration of Cancer. Reports on Public Health and Medical Subjects No. 33. London: Her Majesty's Stationery Office, 1926;1-26.
21. Lakatos E, Lan KK. A comparison of sample size methods for the logrank statistics. Stat Med 1992;11:179-91.